There is a meeting that happens in every healthcare commercial team, usually six weeks after a campaign has closed out, always in a room with too many slides and not enough honesty.
The campaign underperformed. The numbers are on the screen. Someone says "we need to get back to basics" and a particular kind of silence follows. The kind where everyone is nodding, not because they agree, but because the phrase makes the meeting possible to end.
(I have been in this room more times than I would like to count. It is a very convincing room.)
So the team agrees to tighten the product story. Revisit the value proposition. Run another round of message testing with clinical stakeholders. And then they do the whole thing again...
What Usually Happens Next
The conventional response to an underperforming healthcare campaign follows a pattern so familiar I could probably describe the deck before you show it to me.
You audit the creative. You run a survey with a handful of clinical champions to check whether the messaging resonated. You hire a brand consultancy to revisit the positioning. Someone suggests the problem was the agency brief, which leads to a new brief, which leads to a new agency, which leads to a new campaign with the same structural problem underneath it.
The logic is not entirely wrong. Messaging does matter. Brand clarity does matter. Getting closer to clinical needs is always a good idea.
The appeal of this approach is that it is visible and manageable. You can brief a copywriter. You can run message-testing workshops. You can point to a revised deck and say the team has addressed the issue. The activity creates the feeling of momentum, and momentum is what boards ask for in a mid-year review.
It also fits the budget cycle. Redoing creative costs money but stays within marketing's control. Commissioning research feels like due diligence. These are known quantities. Healthcare commercial teams are comfortable with known quantities.
Fair enough, up to a point.
Why This Does Not Fix the Actual Problem
The structural problem is not the messaging. The structural problem is that product management, marketing strategy, and marketing communications are three distinct functions with three distinct failure modes, and conflating them is the source of most underperforming campaigns I have been asked to diagnose.
Let me be specific about what each function actually does.
Product management owns the brief. It defines what needs to be communicated, to whom, at what point in the clinical adoption pathway, and why that message is commercially credible given the evidence base. When product management fails, the brief that goes to the marketing team describes a product, not a commercial problem. The campaign is technically accurate about what the device does and entirely wrong about why anyone should care right now.
Marketing strategy owns the architecture. It decides which channels reach which audience at which stage of the buying journey, how the campaign elements connect, and what success looks like over a twelve to eighteen month horizon. When marketing strategy fails, you can have excellent creative deployed to the wrong audience through the wrong channels at the wrong moment. The message is fine. The structure is wrong.
Marketing communications owns execution. It turns the approved strategy into copy, creative, timing, channel-specific assets, and campaign management. When comms execution fails, the strategy was sound but the campaign itself did not land. Message testing was skipped. The congress activation was generic. The email sequence sent three identical messages to the same list in the same week and wondered why open rates collapsed.
These are not the same failure...
They have different root causes, different diagnostic questions, and critically, different fixes. Going back to product features addresses only the first column. It will not repair a broken distribution strategy. It will not recalibrate an email sequence sending at the wrong frequency. And if the product brief was actually fine to begin with, which happens more often than people admit, you have just spent a quarter rewriting copy that was never the problem.
(The activity metrics improved. The results did not. Which is a sentence I have used in more than one debrief, and which tends to produce a particular kind of uncomfortable silence.)
What Is Actually Happening
Here is what I have observed across forty-seven product launches: the teams that recover fastest from a campaign failure are not the ones that go back to basics. They are the ones that name the specific function that failed, quickly, without defending territory, and redirect energy to fixing only that.
The reason most teams do not do this is structural, not a question of intelligence.
Healthcare marketing in a mid-sized medtech or diagnostics company is typically one team doing all three jobs simultaneously. There is no clean boundary between where product management ends and marketing strategy begins. Nobody has a formal mandate to diagnose which function produced the failure. The post-mortem reviews outputs, not the process that created them.
And there is something else. The "go back to basics" instinct is not purely intellectual. It is partly political. Saying "our comms execution failed" is relatively safe. Saying "the product brief was wrong from the start" implicates a more senior group of people and a longer project history. "We need stronger product messaging" is a story that everyone can live with. It does not require anyone to admit that the architecture was broken before a single piece of creative was made.
The Latin word "decidere" means to cut away. A decision, properly understood, is not about adding something new. It is about cutting away the options that are not working. Most campaign post-mortems in healthcare are exercises in adding: more research, more testing, more creative iterations, more stakeholder consultations. They do not cut. They accumulate.
Going back to basics is adding. It is rarely cutting.
A Different Approach
The diagnostic starts with a single question: at which function did this campaign actually fail?
Not "what should we have said differently?" That assumes the comms layer is where the problem lives. Not "should we have targeted a different audience?" That assumes the strategy layer. The first question is neutral. It does not assume anything.
To answer it, you need three more specific questions.
First question: Was the brief right? Before any creative was made, did the product management team define the specific commercial problem being solved, the audience with the purchasing authority, the moment in their decision process being targeted, and the one thing that would prompt a different behaviour? If any of those four things were unclear or absent, the failure started at the product brief.
Second question: Was the architecture right? Was the campaign designed to build awareness, drive consideration, or accelerate a buying decision? Were the channels matched to the buyer's stage? Was there a logical connection between first exposure and conversion, or did the campaign run parallel activities with no structured flow between them?
Third question: Was the execution right? Given a sound brief and a sound strategy, did the campaign itself perform? Were messages calibrated for each specific channel? Was timing aligned with the clinical calendar and the procurement cycle? Was there any testing before full deployment?
Most campaigns fail the first question. In my experience, somewhere between half and two thirds of the post-mortems I have been part of reveal, on close inspection, that the brief was incomplete before any creative was made. A stronger product story would not have saved them.
(Still working on this rigour ourselves, if I am honest. We ran a diagnostic campaign for a client last year where the brief was technically accurate about the product and entirely silent about what change in clinical behaviour it was designed to create. Caught it six weeks in. Cost us time we did not have.)
The brief describes the product. The strategy describes the buyer. The gap between them is where campaigns fail.
Case Study
A surgical instruments company came to us after two consecutive quarters of underperforming outreach. Their post-mortem had concluded they needed stronger messaging. They had already briefed a copywriter.
We ran the three-function diagnostic before any creative work resumed.
The brief had a structural problem. The product had two distinct clinical applications, one in orthopaedic surgery and one in general surgery, each with a different buying group, a different procurement pathway, and a different decision timeline. The brief had merged them into a single campaign targeting "surgical teams." The messaging felt generic because it was trying to serve two incompatible audiences at once.
The architecture was largely sound. Channel selection was reasonable. Congress presence was well-planned.
The comms execution had one significant gap. The campaign was running on a six-week activity cycle in a specialty where the average procurement decision runs twelve to eighteen months. Every touchpoint was designed for short-cycle conversion in a long-cycle market. The audience was receiving messages that felt premature for where they actually were in the decision process.
The team separated the two audience briefs, adjusted the campaign timeline to match the orthopaedic procurement cycle, and built distinct value propositions for each clinical application. Within two quarters, meeting acceptance rates in orthopaedic surgery moved from 31 percent to 53 percent. General surgery remained flat, which prompted a separate commercial review of whether that audience was worth the investment at all.
The creative was fine. The brief was the problem.
Practical First Steps
If your last campaign underperformed and the instinct is to revisit the messaging, I would suggest doing one thing before writing a single word of new copy.
Sit down with whoever owns each of the three functions, or whoever is closest to each function in your structure, and ask the same question to each of them: what would a successful outcome have looked like at your stage, and did we achieve it?
The product management perspective will tell you whether the brief captured the right commercial problem. The strategy perspective will tell you whether the architecture was built for the right stage and audience. The comms perspective will tell you whether execution performed against the strategy it was given.
This conversation takes about ninety minutes. It will almost certainly produce a different answer than your existing post-mortem.
The second thing: resist the instinct to act immediately. Most campaigns that underperform trigger immediate creative changes, which is the wrong response if the problem was not in the creative. The ninety-minute diagnostic costs nothing and may save you a quarter of wasted spend.
The third thing: accept that you may not have three cleanly separated functions. In many healthcare commercial teams, one person is doing two of these jobs, which makes the diagnostic harder but not impossible. The questions are the same. The functional boundaries are just less defined.
One approach adds until something changes. The other cuts to where the failure actually lives.
The Real Stakes
There are healthcare innovations that deserved a larger commercial life than they got.
Not because the clinical evidence was weak. Not because the market was wrong. Because the campaign designed to create demand diagnosed the failure at the wrong layer and ran the same structural mistake twice.
That is what is happening in those post-mortem meetings. The room agrees on "back to basics" because it is a decision everyone can make without naming what actually went wrong.
The harder question is worth asking.
Which function failed?
What next?